Unknown

Dataset Information

0

Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.


ABSTRACT: Oncolytic vesicular stomatitis virus (VSV) has potent antitumor activity but some cancer cells are resistant to VSV killing, either constitutively or due to type I interferon (IFN) inducing an antiviral state in the cells. Here, we evaluated VSV oncolysis of a panel of human head and neck cancer cells and showed that VSV resistance in SCC25 and SCC15 cells could be reversed with Janus kinase (JAK) 1/2 inhibitors (JAK inhibitor I and ruxolitinib). Pre-treatment of cells with JAK1/2 inhibitors before or in conjunction with VSV enhanced viral infection, spread and progeny yield (100- to 1000-fold increase). In contrast, inhibitors of histone deacetylase (LBH589), phosphatidylinositol 3-kinase (GDC-0941, LY294002), mammalian target of rapamycin (rapamycin) or signal transducer and activator of transcription 3 (STAT3 inhibitor VII) were ineffective. Compared with VSV-sensitive SW579 cells, IFN?/? responsive antiviral genes (IRF-9, IRF-7, OAS1 but not MxA) are constitutively expressed in SCC25 cells. Pretreatment with JAK inhibitors reduced mRNA levels of these genes, increasing VSV expression in the cells. Interestingly, 1?h of drug exposure was sufficient to reverse SCC25 resistance to VSV and was still effective if virus was added 24?h later. Overall, we show here that JAK inhibitor I and ruxolitinib (Jakafi) can reverse resistance to VSV, supporting the rationale to incorporate JAK1/2 inhibitors in future VSV virotherapy trials.

SUBMITTER: Escobar-Zarate D 

PROVIDER: S-EPMC4817541 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.

Escobar-Zarate D D   Liu Y-P YP   Suksanpaisan L L   Russell S J SJ   Peng K-W KW  

Cancer gene therapy 20130913 10


Oncolytic vesicular stomatitis virus (VSV) has potent antitumor activity but some cancer cells are resistant to VSV killing, either constitutively or due to type I interferon (IFN) inducing an antiviral state in the cells. Here, we evaluated VSV oncolysis of a panel of human head and neck cancer cells and showed that VSV resistance in SCC25 and SCC15 cells could be reversed with Janus kinase (JAK) 1/2 inhibitors (JAK inhibitor I and ruxolitinib). Pre-treatment of cells with JAK1/2 inhibitors bef  ...[more]

Similar Datasets

| S-EPMC9194506 | biostudies-literature
| S-EPMC5653517 | biostudies-literature
| S-EPMC8580621 | biostudies-literature
| S-EPMC6454890 | biostudies-literature
| S-EPMC7973277 | biostudies-literature
| S-EPMC7666993 | biostudies-literature
| S-EPMC7447157 | biostudies-literature
| S-EPMC4873128 | biostudies-literature
| S-EPMC5698126 | biostudies-literature
| S-EPMC3111812 | biostudies-literature